文献速递细菌感染、耐药与抗菌药物

加拿大皮肤软组织感染病原对局部抗菌药的体外活性与耐药率

In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18).
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

基于CANWARD 2007-18收集的MSSA、MRSA和化脓性链球菌,采用CLSI肉汤微量稀释法检测夫西地酸、莫匹罗星、奥泽沙星及对照药的体外活性与耐药率。夫西地酸低水平耐药在MSSA和MRSA均超过10%,莫匹罗星高水平耐药在MRSA超过10%,奥泽沙星对包括多重耐药MRSA在内的SSTI病原均有活性。

要点

  • 夫西地酸低水平耐药在MSSA和MRSA均超过10%,高水平耐药≤3.5%。
  • 莫匹罗星高水平耐药在MRSA达14.1%,在MSSA为1.4%。
  • 奥泽沙星对MRSA全部菌株MIC≤0.5 mg/L,包括对多种药物耐药者。

核心结论

  • 夫西地酸低水平耐药在MSSA和MRSA均超过10%,高水平耐药≤3.5%。
  • 莫匹罗星高水平耐药在MRSA超过10%。
  • 奥泽沙星对SSTI病原包括对氟喹诺酮类、大环内酯类、克林霉素、夫西地酸和莫匹罗星耐药的MRSA均有活性。

研究设计与样本

  • 对CANWARD 2007-18收集的SSTI分离株MSSA(n=422)、MRSA(n=283)和化脓性链球菌(n=46)采用CLSI肉汤微量稀释法检测。
  • 夫西地酸低水平耐药定义为MIC≥2 mg/L,高水平耐药定义为MIC≥512 mg/L。
  • 莫匹罗星高水平耐药定义为MIC≥512 mg/L,低水平耐药定义为MIC 2-256 mg/L。

主要发现

  • MSSA中夫西地酸低水平和高水平耐药分别为10.9%和1.7%。
  • MRSA中夫西地酸低水平和高水平耐药分别为10.6%和3.5%。
  • MSSA中莫匹罗星高水平耐药为1.4%,MRSA中为14.1%。
  • 对MSSA,奥泽沙星MIC50和MIC90分别为0.004和0.25 mg/L。
  • 对MRSA,奥泽沙星抑制所有分离株的MIC≤0.5 mg/L,包括环丙沙星MIC>2 mg/L、克拉霉素耐药、克林霉素耐药、夫西地酸高水平耐药和莫匹罗星高水平耐药的分离株。

关键数值与推荐

  • 夫西地酸低水平耐药:MIC≥2 mg/L;高水平耐药:MIC≥512 mg/L。
  • 莫匹罗星高水平耐药:MIC≥512 mg/L;低水平耐药:MIC 2-256 mg/L。
  • MSSA夫西地酸低水平耐药10.9%,高水平耐药1.7%;MRSA低水平耐药10.6%,高水平耐药3.5%。
  • MSSA莫匹罗星高水平耐药1.4%,MRSA高水平耐药14.1%。
  • 奥泽沙星对MSSA的MIC50为0.004 mg/L,MIC90为0.25 mg/L;对MRSA所有菌株MIC≤0.5 mg/L。

临床怎么用

  • 经验性使用夫西地酸或莫匹罗星治疗SSTI时需考虑当地耐药率,尤其MRSA中莫匹罗星高水平耐药超过10%。
  • 奥泽沙星体外对包括多重耐药MRSA在内的SSTI病原均有活性,可作为局部治疗选择参考。

局限性

  • 本研究为体外药敏试验,未评估临床疗效。
  • 仅纳入加拿大CANWARD监测分离株,外推需谨慎。
  • 化脓性链球菌样本量较小(n=46)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current antimicrobial susceptibility/resistance data versus skin and soft tissue infection (SSTI) pathogens help to guide empirical treatment using topical antimicrobials. OBJECTIVES: To assess the in vitro activity and resistance rates of fusidic acid, mupirocin, ozenoxacin and comparator agents against pathogens isolated from patients with SSTIs in Canada. METHODS: SSTI isolates of MSSA (n = 422), MRSA (n = 283) and Streptococcus pyogenes (n = 46) obtained from CANWARD 2007-18 were tested using CLSI broth microdilution. Fusidic acid low-level resistance was defined as an MIC of ≥2 mg/L and high-level resistance as an MIC ≥512 mg/L. Mupirocin high-level resistance was defined as an MIC ≥512 mg/L and low-level resistance was an MIC of 2-256 mg/L. RESULTS: Low-level and high-level fusidic acid resistance in MSSA was 10.9% and 1.7%, respectively. Low-level and high-level fusidic acid resistance in MRSA was 10.6% and 3.5%, respectively. High-level mupirocin resistance was identified in 1.4% of MSSA and 14.1% of MRSA, respectively. Versus MSSA, ozenoxacin demonstrated MIC50 and MIC90 of 0.004 and 0.25 mg/L, respectively. Against MRSA, ozenoxacin inhibited all isolates at an MIC of ≤0.5 mg/L, including isolates with ciprofloxacin MICs >2 mg/L, clarithromycin-resistant, clindamycin-resistant, high-level fusidic acid-resistant and high-level mupirocin-resistant isolates. CONCLUSIONS: We conclude that fusidic acid low-level resistance exceeded 10% for both MSSA and MRSA while fusidic acid high-level resistance was ≤3.5%. Mupirocin high-level resistance exceeded 10% in MRSA. Ozenoxacin is active versus SSTI pathogens including MRSA resistant to fluoroquinolones, macrolides, clindamycin, fusidic acid and mupirocin.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Zhanel GG, Adam HJ, Baxter M, et al. In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18). J Antimicrob Chemother. 2021. PMID: 33792700. doi:10.1093/jac/dkab098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。